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CHAPTER 12
COUNTERFEIT PHARMACEUTICALS 
AND METHODS TO TEST THEM
HARPARKASH KAUR, 
London School of 
Hygiene and 
Tropical Medicine
Pharmaceutical counterfeiting is a global threat that can kill patients, contributes to the 
rise of drug resistance, and increases citizens’ mistrust of health systems.  To monitor drug 
quality, governments and health programs must invest in regulations, technologies, and 
infrastructure, including anti-counterfeiting measures, specialised analytical facilities run by 
experienced staff, and portable technologies for screening medicines in the field.
he United Nations Office on 
Drugs and Crime has identified 
pharmaceutical counterfeiting as 
a global threat1. Although health 
professionals assume that they are prescribing 
good-quality medications, and patients 
believe that these medications will cure them, 
counterfeit drugs are often revealed only after a 
patient fails to recover2.
The medicines supply is carefully monitored 
in the UK, but this is not the case in resource-
constrained countries, where a range of 
factors are contributing to pharmaceutical 
counterfeiting.  These include: lack of legislation; 
weak or absent regulatory authorities; demand 
exceeding supply; the high price of ‘innovator 
drugs’ (i.e. brand-name drugs); the difficulty 
in tracking transactions involving many 
intermediaries; and the lack of laboratories or 
field-tests to assess the quality of drugs. 
Poor-quality medicines are divided into four 
main classes: counterfeit, falsified, substandard 
or degraded. But there are no universally-
accepted definitions of these categories3.  The 
World Health Organization (WHO) defines 
spurious/falsely-labelled/falsified/counterfeit 
(SFFC) drugs as follows4:
“A counterfeit medicine is one which is 
deliberately and fraudulently mislabelled 
with respect to identity and/or source. 
Counterfeiting can apply to both branded and 
generic products and counterfeit products may 
include products with the correct ingredients 
or with the wrong ingredients, without active 
ingredients, with insufficient active ingredient or 
with fake packaging” 
Falsified (fake) medicines do not contain the 
stated active pharmaceutical ingredient (SAPI) 
and may carry false representation of their 
source or identity. (A falsified drug could signal 
a potentially counterfeit product, which does 
not comply with intellectual property rights 
or may infringe trademark law)5. Substandard 
drugs are produced with inadequate attention 
to good manufacturing practices and may 
have contents or dissolution times that are 
outside accepted limits, due to poor quality 
control6. Degraded formulations may result 
from exposure of good-quality medicines to 
light, heat, and humidity. It can be difficult to 
distinguish degraded medicines from those 
that left the factory as substandard, but the 
distinction is important because the causes and 
remedies will be different.
The WHO’s International Medical Products 
Anti-Counterfeiting Taskforce (IMPACT) 
estimates that up to 25% of the total 
medicine supply in less-developed countries 
is counterfeit7. Obtaining exact figures is very 
difficult, however, as the very nature of this 
trade means that it attempts to operate below 
the regulatory radar, and many suspect drugs 
remain undetected.  The prevalence of poor 
quality drugs can only be known after a formal 
drug quality survey has been performed, and 
objective evidence of the quality of drugs 
available from most countries is lacking.
Alarmingly, if a medicine contains too few 
active pharmaceutical ingredient (APIs) to 
kill all the pathogens in a patient’s body, it 
encourages the emergence of drug resistant 
strains. And because the poor are often limited 
to buying not just the cheapest product, but 
also the smallest pack size, that also makes it 
more likely that they receive inadequate doses 
of an active ingredient, further accelerating 
drug resistance. Poor quality medicines may 
also lead to distrust in the healthcare system 
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and threaten decades of progress in public 
health. It is simply unacceptable that the 
quality of drugs is poor or uncertain for the 
most disadvantaged people, who have the 
least resources and are attracted by the lower 
prices of counterfeit drugs. 
ANTI-COUNTERFEITING 
TECHNOLOGIES 
Several countries have recently ratified legislation 
to combat the sales of falsified medicines.  The 
United States passed the drug quality and 
security act8, while China and India have brought 
in legislation to use bar codes and adopt track-
and-trace systems to check that quality-assured 
medications reach patients.  Tagging technologies 
include radio-frequency identification or 
RFID9, Microtags10, NanoEncryption™ 11 and 
AuthentiTrack® 12, which allow manufacturers 
and distributors to track medicines through 
the supply chain. Microtags are micrometer-
sized particles uniquely encoded with multiple 
levels of security information within a space of 
50–110 micrometers (the size of a speck of 
dust).  The tags are made of inert materials, are 
safe for human consumption and will not alter 
the potency of the medicine.  The information 
they carry can be decoded with laser pens, 
optical scanners or other scanning technologies 
provided by the Microtag maker.
Global alarm about the emergence of 
antibiotic-resistant ‘superbugs’ is prompting wider 
use of these tagging technologies. In developing 
countries, generic antibiotics can be obtained 
without a prescription and little is known about 
their quality. Misuse of antibiotics – through 
unnecessary over-prescribing and sub-optimal 
dosing resulting from substandard antibiotics – 
engenders the development of resistance.  The 
sheer volume of antibiotics sold daily, and their 
relatively low production cost, makes them a 
vulnerable target for counterfeiters, illegitimate 
internet pharmacies, and drug manufacturers 
who use poor manufacturing practices. 
Antimalarial drugs are another vulnerable 
target. Considerable technical, financial and 
human resources are required to inspect, 
analyse and police the drug supply, all of which 
are lacking in most malaria-endemic countries. 
A systematic review of the literature reported 
that few surveys of antimalarial medicines used 
robust methodology, and that the majority 
did not differentiate between substandard 
and counterfeit medicines13. Surveys require 
epidemiological knowledge, and an adequate 
sample size from as wide a range of outlets as 
possible, to provide a reliable estimate of the 
frequency of poor quality drugs. 
Reliable surveys are essential to justify and 
promote the political action that would create 
the mechanisms needed to assure drug quality14.
METHODS TO TEST MEDICINES 
1. Visual and physical inspection 
The first step in determining the quality of a 
medicine is to look for the key features of any 
high-quality medicine.  The package should 
include a list of active ingredients, the name and 
address of the manufacturer, storage conditions, 
batch or lot number, dates of manufacture and 
expiry, and directions for use. An instruction 
leaflet (in the appropriate language and without 
any spelling errors) should be enclosed with 
the tablets.  The tablets themselves should 
match the authentic product in their shape, 
size, and colour. If the solid dose formulation is 
crumbling, chipped or cracked, it may indicate 
a substandard or degraded medicine. However, 
in my experience it can be difficult to persuade 
manufactures to supply genuine product for 
comparison. Pharmaceutical manufacturers 
employ overt anti-counterfeiting strategies 
such as visible holograms, as well as invisible 
covert features to mark the authenticity of 
their products. Sadly, holograms can also be 
counterfeited, as was the case for packages 
of antimalarial artesunate in South East Asia 
that claimed to be manufactured by Guilin 
Pharmaceutical Co. Ltd15.
2. Laboratory tests 
A well-equipped medicines quality control 
laboratory (MQCL) is a crucial component 
of any drug quality assurance system. It 
THE SHEER VOLUME OF ANTIBIOTICS 
SOLD DAILY AND THEIR RELATIVELY 
LOW PRODUCTION COST MAKES THEM 
A VULNERABLE GROUP OF DRUGS FOR 
TARGETING BY COUNTERFEITERS
134
should be equipped with a range of analytical 
equipment (see below), as well as quality-
assured reference standards, all of which is 
cost intensive. An MQCL also requires staff 
with a high level of technical expertise and 
experience of method development. 
High-performance liquid 
chromatography (HPLC) is an analytical 
technique used to separate specific 
compounds, and then identify and quantify 
them based on how long they take to separate, 
and their spectrophotometric properties. 
HPLC can be coupled to various detectors, 
but the ultraviolet photodiode array (UV-
PDA) is regarded as the ‘gold standard’ for 
drug quality analysis because it offers accuracy, 
specificity and precision in quantifying the 
amount of APIs present. It is, however, relatively 
expensive and requires greater expertise to 
operate, which demands extensive training and 
technological support.
HPLC can also be coupled to a mass 
spectrometer (LC-MS). Although this gives 
analysts abundant chemical information, it 
also relies on tedious, time-consuming sample 
preparation, and typically requires a reference 
standard to determine API levels.
However, more recent MS technologies 
avoid sample preparation and give almost 
instantaneous results. Direct analysis in real 
time (DART) MS allows the analyst to hold a 
tablet in front of a mass spectrometer and get 
information about its composition in seconds16, 
while desorption electrospray ionization 
(DESI) MS involves spraying a solvent at the 
tablet to free APIs for analysis17. 
Dissolution testing offers a valuable 
prediction of the in vivo bioavailability and 
bioequivalence of tablets and capsules, by 
measuring the amount of drug released 
into a dissolution media (liquid) over time.  
The presence of incorrect excipients, as 
well as poor manufacturing processes, may 
contribute to poor dissolution resulting in 
lower bioavailability. Indeed, an epidemic 
of malaria on the Afghan-Pakistan border 
was confirmed to result from the poor 
bioavailability of locally-procured substandard 
antimalarial drugs18.  These tests require a 
sophisticated dissolution apparatus, as well as 
analytical equipment (HPLC with UV-PDA) 
and reference standards, which are expensive 
and may be difficult to obtain. Furthermore, 
analysts need to have access to the dissolution 
information that is expected for each 
medication, and the tests are both labour- and 
cost-intensive.
Nuclear magnetic resonance (NMR) 
spectroscopy is a powerful tool that allows 
analysts to determine the structures and 
relative concentrations of molecules in 
a sample without active pharmaceutical 
reference standards. For example, NMR 
analysis of the hydrogen and phosphorous (1H 
and 31P) atoms in the anti-leishmanial drug 
miltefosine helped to prove that a generic 
version procured from Bangladesh did not 
contain the SAPI19. 
3. Screening techniques
Thin layer chromatography (TLC) is an 
inexpensive, simple, flexible and effective 
method for verifying the identity of a 
formulation. It requires a variety of chemical 
reagents and plates, reference standards of 
the SAPIs, and some basic training for the 
analyst. For example, two TLC-based tests can 
check the quality (falsified or authentic) of the 
most effective antimalarial drugs, artemisinin 
combination therapies (ACTs), in the absence 
of a MQCL20.
Many developing countries do not have 
the technical, financial, or human resources 
required to inspect and police the drug 
supply7.  Thus simple and affordable field 
methods provide a practical means of rapidly 
monitoring drug quality. Portable labs – in 
particular the Minilab®, a ready-to-use TLC 
CONVENIENCE SURVEYS CONDUCTED IN SOUTH EAST ASIA IN 2000/1 
AND 2002/3 SUGGESTED THAT 38% AND 53% OF THE ARTESUNATE 
BLISTER PACKS OBTAINED FROM PHARMACIES AND SHOPS WERE 
COUNTERFEIT.  
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kit from the German Pharma Health Fund 
(GPHF)21 – provides a versatile means for 
initial screening of many drug formulations, 
including antimicrobials, antimalarials, and 
antiretrovirals. Currently 713 GPHF-Minilab 
units are used globally across 92 countries to 
fight the counterfeit drug trade.  
The Tanzanian Food and Drugs Authority 
pilot-tested the Minilab® and found it to be 
relatively inexpensive and rapid, but that it 
detected only grossly substandard or wrong-
drug samples. Ultimately, the Minilab® should 
be used in conjunction with robust laboratory-
based testing22.  This approach was recently 
used to assess the quality of two brands of 
antibiotics, amoxicillin and co-trimoxazole, 
manufactured in six countries and purchased 
in Ghana, Nigeria and Nigeria. All of the 
samples of amoxicillin complied with United 
States Pharmacopeia (USP) tolerance limits for 
dissolution testing, but 60% of co-trimoxazole 
tablets did not. But there was some disparity 
in the Minilab® results, highlighting that this 
portable laboratory should not be relied upon 
to make regulatory decisions23.
4. Portable instruments
Hand-held devices based on spectroscopic 
methods are now being investigated as 
screening tools that can rapidly detect poor-
quality drugs throughout the supply chain 
(see case study p138). Non-destructive 
spectroscopic techniques such as Raman 
spectroscopy and near infrared (NIR) 
are currently being evaluated for their ability 
to scan drug samples through the blister 
pack, without using the toxic chemicals 
or flammable solvents typically found in a 
MQCL. Both techniques rely on comparing 
characteristic spectral ‘fingerprint’ of a 
suspect medicine with a genuine sample.  This 
necessitates access to a database of spectra, 
created by investigators, for every brand of 
medications from every manufacturer (see 
case study, p140).
One potential drawback of using Raman 
spectroscopy is that only the sample surface is 
probed, so if the SAPI is not evenly distributed 
throughout the entire tablet, the resulting 
content information may be inaccurate. 
Additionally, many pharmaceutical preparations 
contain highly fluorescent excipients, thus 
affecting the quality of the spectrum.  The 
TruScan® hand-held Raman device has 
successfully detected some counterfeits in 
the field, but it has not been useful to detect 
substandard medicines24. 
Unlike Raman spectroscopy, infrared (IR) 
spectroscopy has a larger depth penetration into 
the sample surface. Near-infrared spectroscopy 
(NIR) can reveal whether excipients are not 
in the correct proportions, suggesting that the 
medicine is counterfeit, but it cannot detect 
substandard medicines25.  NIR is also relatively 
simple to miniaturise: for example, the SCiO 
NIR device, at present under validation, is a 
smart-phone-sized instrument that promises 
to be highly effective at checking the quality 
of medications in the absence of a MQCL26. 
Meanwhile, the US Food and Drug Administration 
(FDA) has recently started using its Counterfeit 
Detection Device CD-3 to screen tablets, 
packaging and even documents at ports of entry 
or in remote areas, although further development 
is still needed27.
QUALITY OF ANTIMALARIAL DRUGS 
IN MALARIA-ENDEMIC COUNTRIES 
A recent meta-analysis reported that 35% of 
antimalarial drug samples from 21 Sub-Saharan 
African countries, failed chemical content 
analysis28.  The underlying research predominantly 
used the ‘convenience’ sampling approach, where 
research teams purchased medicines from drug 
sellers who were easily-accessible, or who were 
already thought to sell poor-quality medicines. 
Results based on this low-cost sampling 
approach can be useful in drawing attention to 
a potential problem. For example, convenience 
surveys conducted in South East Asia in 2000/1 
and 2002/3 suggested that 38% and 53% of 
the artesunate blister packs obtained from 
pharmacies and shops were counterfeit29.  
But the convenience approach may not be 
A RECENT META-ANALYSIS REPORTED 
THAT 35% OF ANTIMALARIAL DRUG 
SAMPLES FROM 21 SUB-SAHARAN 
AFRICAN COUNTRIES, FAILED 
CHEMICAL CONTENT ANALYSIS. 
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SAMPLING  
APPROACH ADVANTAGES DISADVANTAGES
CONVENIENCE • Rapid
• Low cost
•  Lack of defined sampling frame of standardised 
approach
•  Uncertainty in whether sampling is representative 
and therefore reliability of the estimates of drug 
quality obtained
•  Generalisability of findings may be weak
•  Results may be difficult to replicate
MYSTERY 
CLIENTS
•  Use of defined sampling frame
•  Can yield representative sample from all types of 
outlets and/or brands 
•  Low risk of sampling bias in samples collected, as 
outlets are unaware of survey
•  Reliability and generalisability of results should be 
strong
• Results can be replicated
•  Sample will only be as comprehensive and/or 
representative as the sampling frame that was 
used
•  Need to authenticate and update sampling frame 
increases time and cost of survey 
•  Information on sources of poor quality drugs 
is limited to brand, batch and country of 
manufacture as stated on packaging
OVERT •  Use of defined sampling frame
•  Can yield representative sample from all types of 
outlets and/or brands 
•  Results can be replicated
•  Can collect additional information at minimal 
additional cost to mystery approach
•  Sample will only be as comprehensive and/or 
representative as the sampling frame that was 
used 
•  Need to authenticate and update sampling frame 
increases time and cost of survey
•  Possible risk of sampling bias in samples collected, 
if some outlets refuse to be sampled or are 
aware of which samples might be poor quality 
and differentially withhold these
•  Reliability and generalisability of results may be 
compromised if sampling bias occurs
Table 1:   Comparative strengths and weaknesses of the three sampling approaches used
representative of the places where patients 
actually buy their medicines, and it may also be 
biased: for example, if the collector consciously 
or subconsciously set out to procure or not 
procure poor-quality formulations (see Table 1)30.
In 2006, the WHO banned malaria 
medicines that contain just one active 
ingredient (such as artesunate), in favour of 
artemisinin combination therapies (ACTs) that 
contain more than one active ingredient.  This 
treats the disease more rapidly: the artemisinin 
component kills the majority of the parasites 
at the start of the treatment, while the more 
slowly-eliminated partner drug clears the 
remaining parasites, in the hope that resistance 
will be slowed enough to allow for the 
development of a pipeline of efficacious drugs. 
Once ACTs had been enforced in malaria-
endemic countries, it was believed that they 
would be in danger of being counterfeited. 
Hence, the Artemisinin-based Combination 
Therapy Consortium Drug Quality programme 
purchased over 10,000 artemisinin-containing 
antimalarials (ACAs) in 6 malaria endemic 
countries, from private sector retail outlets 
such as pharmacies and drug shops, following 
representative sampling approaches31. Outlets 
were selected at random in most countries 
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from lists obtained from the relevant 
government’s ministry of health; whereas 
in other countries we initially conducted a 
pilot study by collecting samples using the 
‘convenience’ approach to gain perspective 
on the type of outlets and brands of ACAs 
available. 
Medicine samples were subsequently 
purchased using one of two approaches.  
Through the ‘mystery client’ approach, the 
person purchasing the medicines posed as a 
malaria patient or their relative; through ‘overt 
sample collection’, vendors were informed 
that we were going to analyse the quality of 
the medicines they sold, and samples were 
purchased once they consented.  This allowed 
us to interview the vendor to obtain data 
on the availability and supply of antimalarials, 
their storage conditions, and the training of 
providers. 
The collected samples were analysed in 
three different laboratories in the UK and the 
US. First, they were sent to the London School 
of Hygiene and Tropical Medicine (LSHTM), 
where they were logged and their packaging 
and blister packs scanned. Each tablet was 
weighed and its dimensions recorded on the 
database. Each sample was analysed using 
HPLC UV-PDA to measure the amount 
of APIs, which was then expressed as the 
percentage of the SAPIs and used to classify 
the quality of the sample. Duplicate samples 
from each packet of tablets analysed at LSHTM 
were sent to the US Centers for Disease 
Control and Prevention in Atlanta, where a 
random 10% were analysed for confirmatory 
HPLC-PDA results. A duplicate set was also 
sent to the Georgia Institute of Technology, 
Atlanta, for ambient MS analyses to verify the 
pharmaceutical ingredients present and identify 
any unstated compounds. Samples were 
classified as ‘acceptable quality’ if the SAPIs 
were present at between 85% and 115% of 
the SAPI quantity. Medicines outside this range, 
for either or both of the partner compounds, 
were classified as substandard.  These 
substandard medicines were also examined to 
detect the presence of degradation products, 
caused by poor storage conditions such as 
heat and humidity. Medicines were regarded 
as falsified when either one of the SAPIs was 
not present. All results were compiled into 
a report and disseminated to the relevant 
ministries of health before being submitted as a 
manuscript to peer reviewed journals.
In these investigations of ACAs, we found no 
evidence of falsified medicines in 4,928 samples 
(over 50 brands) from Cambodia, Ghana, 
Rwanda and Tanzania. Of the 5,151 samples 
that were collected in Bioko Island (Equatorial 
Guinea) and Nigeria (over 142 brands), 1.9% 
were falsified i.e. they contained neither of 
the SAPIs. Instead, they contained compounds 
including chlorzoxazone (a muscle relaxant), 
ciprofloxacin (an antibiotic) or acetaminophen 
(paracetamol, a commonly used painkiller).  
The falsified medicines found in this research 
are far fewer than the 35% fakes suggested in 
previous reports. However, it is worth noting 
that substandard drugs were found in all the 
countries that we studied, with the most in 
Cambodia (31.3%), Ghana (37%) and Tanzania 
(12%); others were less than 8%.
The key strengths of this investigation are 
that representative sampling approaches were 
used to purchase a sizeable number of samples; 
these were analysed in three independent 
laboratories, using two different detection 
methods (HPLC with UV-PDA and MS)30.
Representative methods to sample 
medicines are important for generating 
reliable estimates of the prevalence of poor 
quality drugs in a given country. However, this 
type of study is cost intensive, both for the 
purchase and analysis of drugs. It is important 
to establish affordable systems that sample 
medicines in a representative way, and develop 
robust laboratory techniques to analyse them 
on a regular basis.  This will enable for the 
accurate quantification and tracking of the 
scale of poor-quality medicines that threaten 
the treatment of this life threatening disease. 
WE NEED GREATER INVESTMENT 
IN DEVELOPING AND VALIDATING 
PORTABLE TECHNOLOGIES THAT 
CAN BE USED IN THE FIELD.  
